Daluzo represents a innovative protein, distinctly developed as an engineered targeted protein aimed at DLL3 standard ligand 3 (DLL3), who plays a key role in blood-forming progenitor lineage growth and malignant blood angiogenesis. This compound, referred to as Dalotuzumab, exhibits promising medicinal activity in patients diagnosed with acute mye